Processing

Please wait...

Settings

Settings

1. CA2615447 - SUBSTITUTED AMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS

Office Canada
Application Number 2615447
Application Date 17.07.2006
Publication Number 2615447
Publication Date 25.01.2007
Publication Kind A1
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7
Drugs for disorders of the blood or the extracellular fluid
02
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
513
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/, C07D477/232
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C07D 409/14
A61K 31/55
A61P 7/02
C07D 513/04
CPC
C07D 513/04
C07D 409/14
Applicants BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Inventors GERLACH, KAI
PRIEPKE, HENNING
PFAU, ROLAND
WIENEN, WOLFGANG
SCHULER-METZ, ANNETTE
DAHMANN, GEORG
Priority Data 05015588.6 19.07.2005 EP
Title
(EN) SUBSTITUTED AMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
(FR) AMIDES SUBSTITUES, LEUR PREPARATION ET LEUR UTILISATION EN TANT QUE MEDICAMENT
Abstract
(EN)
The present invention provides new substituted amides of the general formula (I) in which D, L, M, W and B are as defined in the description, their tautomers, their enantiomers, their diastereomers, mixtures thereof and salts thereof, particularly their physiologically acceptable salts with organic or inorganic acids or bases, which have valuable properties. The compounds act as inhibitors of factor Xa.